[HTML][HTML] An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure …
[HTML][HTML] Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
[PDF][PDF] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
[HTML][HTML] Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
…, SK Zepeda, K Culap, D Pinto, LA VanBlargan… - Nature, 2022 - nature.com
The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …
[PDF][PDF] A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2
The coronavirus disease 2019 pandemic has made deployment of an effective vaccine a
global health priority. We evaluated the protective activity of a chimpanzee adenovirus-…
global health priority. We evaluated the protective activity of a chimpanzee adenovirus-…
[PDF][PDF] Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
N Suryadevara, S Shrihari, P Gilchuk, LA VanBlargan… - Cell, 2021 - cell.com
Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike (S)
protein receptor-binding domain and block virus interactions with the cellular receptor …
protein receptor-binding domain and block virus interactions with the cellular receptor …
[HTML][HTML] In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
…, B Ying, JM Errico, S Shrihari, LA VanBlargan… - Nature, 2021 - nature.com
Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …
[HTML][HTML] Defining the risk of SARS-CoV-2 variants on immune protection
…, SA Turner, MA Vakaki, H van Bakel, LA VanBlargan… - Nature, 2022 - nature.com
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants jeopardizes the protective antiviral immunity induced after infection or …
variants jeopardizes the protective antiviral immunity induced after infection or …
Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice
New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue
to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a …
to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a …
Dengue viruses cluster antigenically but not as discrete serotypes
The four genetically divergent dengue virus (DENV) types are traditionally classified as
serotypes. Antigenic and genetic differences among the DENV types influence disease outcome, …
serotypes. Antigenic and genetic differences among the DENV types influence disease outcome, …